UBS and JPMorgan Provide Debt Financing to Carlyle Acquisition of WellDyneRx
September 07, 2016
NEW YORK – Paul Hastings LLP, a leading global law firm, represented UBS and JPMorgan as the committed debt financing providers and lead arrangers in connection with Carlyle Partners’ definitive agreement to acquire all outstanding shares of WellDyneRx, Inc., a privately-held U.S.-based pharmacy benefit manager providing full-service prescription drug management between patients and drug plans through a network of retail providers in addition to a mail order and specialty drug pharmacy.
Equity for the transaction will come from Carlyle Partners VI, a $13 billion fund that focuses on buyout transactions in the U.S. The financing consists of a $50 million revolving credit facility, a $315 million first lien term loan facility and a $140 million second lien term loan.
The Paul Hastings team was led by Leveraged Finance partner
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.